NICE recommends Cinqaero (reslizumab) for treatment of severe asthma
The National Institute for Health and Care Excellence (NICE) in…
The National Institute for Health and Care Excellence (NICE) in England has recommended Teva Pharmaceutical Industries Ltd’s Cinqaero (reslizumab) in its Final Appraisal Determination (FAD).